Advertisement
Canada markets open in 7 minutes
  • S&P/TSX

    22,269.12
    +197.42 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.82 (+1.51%)
     
  • CAD/USD

    0.7340
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    76.56
    -0.43 (-0.56%)
     
  • Bitcoin CAD

    94,778.32
    +2,172.39 (+2.35%)
     
  • CMC Crypto 200

    1,500.12
    +32.18 (+2.19%)
     
  • GOLD FUTURES

    2,354.40
    +8.60 (+0.37%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.4690
    -0.0450 (-1.00%)
     
  • NASDAQ futures

    18,693.50
    +102.50 (+0.55%)
     
  • VOLATILITY

    13.13
    +0.21 (+1.63%)
     
  • FTSE

    8,300.73
    +25.35 (+0.31%)
     
  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     
  • CAD/EUR

    0.6764
    +0.0002 (+0.03%)
     

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del., May 21, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

ADVERTISEMENT

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521754461/en/

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com